𝔖 Bobbio Scriptorium

✦ LIBER ✦

Have the ultimate benefits of clinical trials been maligned beyond repair?

✍ Scribed by Kathleen B Drennan

Book ID: 114383554
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 30 KB
Volume: 6
Category: Article
ISSN: 1359-6446
DOI: 10.1016/s1359-6446(01)01813-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Beyond Lipid Lowering: What Have We Lear

Beyond Lipid Lowering: What Have We Learned About the Benefits of Statins from the Acute Coronary Syndromes Trials?

✍ Kausik K. Ray; Christopher P. Cannon; Peter Ganz 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Assessing clinical benefit response in t

Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer

✍ Haruhiko Imamoto; Koji Oba; Junichi Sakamoto; Hiroyasu Iishi; Hiroyuki Narahara; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 259 KB

Large U.S. clinical trials report a high

Large U.S. clinical trials report a high proportion of H. Pylori negative duodenal ulcers at study entry as well as a high recurrence rate after cure of the infection: Have we all been wrong?

✍ D.Y. Graham 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Cardiovascular safety of lercanidipine i

Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials: by Specchia et al, which appeared in the January 2001 issue, the number of patient months in the analysis should have been 4,988,000 instead of 2,731,000.

📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 21 KB

MAGNA CARTAThe Great CharterPreamble

MAGNA CARTAThe Great CharterPreamble

📂 Fiction 🌐 English ⚖ 11 KB 👁 18 views